Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity

BACKGROUND: Immune checkpoint blockade (ICB) treatment may induce durable disease remission, but only in a minority of patients with cancer. One important question is how to identify patients who may benefit from ICB treatment. ICB treatment relies on unleashing patients’ pre-existing immune respons...

Descripción completa

Detalles Bibliográficos
Autor principal: Zheng, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008381/
https://www.ncbi.nlm.nih.gov/pubmed/36889809
http://dx.doi.org/10.1136/jitc-2022-006462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008381/
https://www.ncbi.nlm.nih.gov/pubmed/36889809
http://dx.doi.org/10.1136/jitc-2022-006462

Ejemplares similares